Medidata Appoints New China GM and Doubles Size of Talent in Region
28 June 2018 - 10:30PM
Business Wire
Accelerating Innovation and Adoption for
Industry Leading eClinical Platform
With China based customers doubling in 2017, Medidata (NASDAQ:
MDSO) announced the appointment of Jim (Hui) Xu as general manager
in the market, and plans to double the size of local talent. Recent
regulatory changes in China are promoting faster drug approvals,
and large sponsors and partners such as Fosun Pharma, BeiGene, and
WuXi CDS are joining the Medidata Cloud, the Intelligent Platform
for Life Sciences for over 1,000 global biotechnology,
pharmaceutical and medical device companies.
Jim Xu brings over 24 years of unique leadership experiences
across healthcare technology and IT industries, both in China and
the US. Recently he served as CEO of the China division of
Caradigm, a GE Healthcare company, where he set up local operations
and spearheaded the company’s growth strategies. He has also worked
in the health solutions divisions at Microsoft and GE
Healthcare.
“We’re excited about our fast growth and momentum in China.
Jim’s experience facilitating go-to-market strategies, product
commercialization and successful sales performance will support the
high demand for our innovative solutions tailored for the region,”
said Edwin Ng, vice president, field operations, APeJ of
Medidata.
The pharmaceutical market in China is forecasted to reach $167
billion by 2020, representing an annual growth rate of 9.1%. To
meet this growing global demand, local drug and device developers
are rapidly adopting the Medidata Cloud to enhance their global
footprint and drive efficient clinical trials with a proven and
scalable platform. Medidata’s unified platform is seamlessly
supporting China based companies as they address new global
regulations, including ICH E6, and execute on their strategy to
expand global studies beyond the region.
"China is a key region for life sciences, becoming the second
largest pharmaceutical market in the world and growing rapidly
driven by patient needs and innovation. Jim's appointment allows us
to help our China based customers and partners leapfrog the market
and accelerate research innovation,” said Tarek Sherif, chairman
and chief executive officer, Medidata. “Only Medidata can connect
global and local CROs to the right sponsors and streamline the way
global companies develop products and bring them to market. Our
unified platform, pioneering analytics and data, and unrivaled
expertise is powering the digital transformation of life sciences
globally and provides unique value in China.”
The Medidata NEXT event series is in Seoul July 10 and Shanghai
July 12. Join Medidata executives and global life science industry
leaders to discuss the future of drug development.
About Medidata
Medidata accelerates the digital transformation of life sciences
through its unified platform, pioneering analytics, and unrivaled
expertise. The Intelligent Platform for Life Sciences seamlessly
delivers market-leading applications powered by artificial
intelligence and real-world analytics to reduce risk, optimize
revenue, and ultimately help patients.
More than 1,000 pharmaceutical companies, biotech, medical
device firms, academic medical centers and contract research
organizations around the world can now manage and optimize value
across the clinical and commercial continuum. For more information:
www.mdsol.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180628005326/en/
Medidata SolutionsInvestors:Betsy Frank, +1
917-522-4620bfrank@mdsol.comorMedia:Erik Snider, +1
646-362-2997esnider@mdsol.com
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From Apr 2024 to May 2024
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From May 2023 to May 2024